Allergy
Therapeutics
plc
("Allergy Therapeutics" or "the Group")
Allergy Therapeutics presents
scientific findings from research portfolio at EAACI
2024
31
May 2024 Allergy Therapeutics plc
(AIM: AGY), the integrated commercial biotechnology company
specialising in allergy vaccines, today announces that it will be
sharing key scientific findings from across its research portfolio
at the European Academy of
Allergy and Clinical Immunology (EAACI)
Congress, taking place from
today until 3 June 2024 in Valencia, Spain.
The EAACI Congress is the world's
largest scientific conference that specialises in the field of
allergy and clinical immunology and the flagship meeting of the
European Academy of Allergy and Clinical Immunology, an association
of more than 16,000 clinicians, researchers and allied health
professionals from 124 countries, dedicated to improving the health
of people affected by allergic diseases.
Among its 12 posters being
presented, Allergy Therapeutics will share:
· The
positive results from the pivotal Phase III G306 trial, which
evaluated the efficacy and safety of Grass MATA MPL, the Group's
short-course subcutaneous allergen-specific immunotherapy (SCIT)
candidate that aims to address the cause of symptoms of allergic
rhinoconjunctivitis due to grass pollen. The trial successfully met its primary endpoint, as previously
announced on 14 November 2023. The findings
from the G306 trial, alongside results of the earlier G309
exploratory field study, will support the Group's marketing
authorisation application (MAA), with a planned submission in Q4
2024.
· Results from analysis of patient and caregiver preferences for
different venom and pollen immunotherapy approaches and their
implications on adherence and treatment acceptance.
· The
beneficial safety and tolerability results from the healthy subject
subcutaneous dosing cohorts of the Phase I/IIa PROTECT trial of the
Group's novel virus-like-particle (VLP)-based peanut allergy
vaccine candidate ("VLP Peanut"), without any major safety or
tolerability findings. This ongoing trial progressed in March 2024
to subcutaneous dosing of peanut allergic patients, marking the
start of the clinical proof of concept phase using biomarkers to
assess preliminary efficacy.
Allergy Therapeutics will also be
hosting a symposium, "Setting a
new standard for grass subcutaneous immunotherapy," on
Sunday, 2 June, 13:45-14:45 CEST, chaired by Professor Dr. Stefan
Zielen, Head of the Institute for Respiratory Medicine, Frankfurt,
Germany. The symposium will include presentations covering
regulatory and clinical challenges in allergen immunotherapy
trials, as well as results from the Group's pivotal Phase III G306
trial of Grass MATA MPL by key experts from the US and
EU.
In addition, Prof. Mohamed Shamji
from Imperial College, London and EAACI Vice President Congresses,
will showcase the Group's scientific adaptive approaches to
clinical development, as applied in the successful G309
and G306
studies, as examples of current state-of-the-art
clinical development in a plenary session.
Finally, Prof. Shamji will host an
embargo session at the closure day of the EAACI conference to
release the Group's recently accepted VLP Peanut paper in the peer
reviewed Journal of Allergy and
Clinical Immunology, the official publication of the
American Academy of Allergy, Asthma, and Immunology (AAAAI). This
session will highlight the promising biomarker safety and efficacy
profile of VLP Peanut, including the first clinical results
supporting the hypo-allergic profile of VLP Peanut based on the
skin test results from the PROTECT Phase I/IIa study.
Manuel Llobet, Chief Executive Officer at Allergy
Therapeutics, said: "At Allergy
Therapeutics, our mission is to transform lives by breaking new
ground in immunology treatments, and we are thrilled to have such a
robust presence at this year's EAACI Congress. The research we are
sharing demonstrates the strength of our science and, with one
innovative short-course allergy immunotherapy targeting peanut
allergy currently in the clinic and another targeting grass pollen
allergy progressing towards a planned market authorisation
application, we are steadfast in our commitment to helping patients
change the way they think about their allergies and better manage
their conditions."
The complete list of Allergy
Therapeutics-sponsored abstracts accepted by EAACI for presentation
are available on the Group's website.
No new material price sensitive
information is expected to be disclosed on Allergy Therapeutics at
the EAACI Congress 2024.
Allergy Therapeutics'
Symposium
Setting a new standard for
grass subcutaneous immunotherapy
Sunday, 02 June; 13:45-14:45
(CEST)
|
Introduction
Chair:
Professor Dr. Stefan Zielen, Head of the Institute for Respiratory
Medicine, Frankfurt, Germany
|
Welcome and
introduction
|
Speaker
Professor
Dr. med. Markus Ollert, Director of the Department of Infection
& Immunity, Luxembourg Institute of Health, Esch-sur-Alzette,
Luxembourg
|
The journey
to registration: Challenges for allergen immunotherapy
trials
|
Speaker
Dr.
Lawrence DuBuske, Clinical Professor of Medicine, George Washington
University School of Medicine, Washington, DC, United
States
|
Challenge
accepted: Results from the pivotal Grass Phase III clinical
trial
|
All
Speakers
|
Q&A
session
|
ENDS
For further information,
please contact:
Allergy Therapeutics
Manuel Llobet, Chief Executive
Officer
Shaun Furlong, Chief Financial
Officer
+44 (0)1903 845 820
Panmure Gordon (Nominated Adviser and
Broker)
Emma Earl, Freddy Crossley, Mark
Rogers, Corporate Finance
Rupert Dearden, Corporate
Broking
+44 (0)20 7886 2500
ICR
Consilium
Mary-Jane Elliott / David Daley /
Davide Salvi
+44 (0)20 3709 5700
allergytherapeutics@consilium-comms.com
Notes for editors:
About Allergy Therapeutics
Allergy Therapeutics is an
international commercial biotechnology company, headquartered in
the UK, focussed on the treatment and diagnosis of allergic
disorders, including aluminium free immunotherapy vaccines that
have the potential to cure disease. The Group sells proprietary and
third-party products from its subsidiaries in nine major European
countries and via distribution agreements in an additional ten
countries. Its broad pipeline of products in clinical development
includes vaccines for grass, tree, house dust mite and peanut. For
more information, please see www.allergytherapeutics.com.